Lynk Pharmaceuticals Competitors and Similar CompaniesClear all

Lynk Pharmaceuticals's competitors and similar companies include Pfizer, Rigel Pharmaceuticals, Ajinomoto Bio-Pharma Services and BridgeBio.

	Lynk Pharmaceuticals Lynk Pharmaceuticals (also known as 凌科药业) is a biotech company engaged in the research and development of medicines to treat autoimmune and inflammation diseases, as well as cancer.	Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.	Rigel Pharmaceuticals Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases.	Ajinomoto Bio-Pharma Services Ajinomoto Bio-Pharma Services (formerly known as Ajinomoto Althea) is a contract development and manufacturing organization (CDMO).	BridgeBio BridgeBio is a company focused on discovering and developing drugs for patients with grievous genetic diseases.
Founding Date	Founding Date 2018	Founding Date 1849	Founding Date 1996	Founding Date 1998	Founding Date 2014
Type	Type Private	Type Public	Type Public	Type Subsidiary	Type Public
Tags	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma
Locations	Locations Hang Zhou Shi, CN HQ	Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more	Locations South San Francisco, US HQ	Locations San Diego, US HQ Wetteren, BE Visakhapatnam, IN Osaka, JP	Locations Palo Alto, US HQ
Employees	Employees 20	Employees 81,0008% decrease	Employees 1633% increase	Employees 68610% decrease	Employees 24863% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) 163.9 b	Valuation ($) 256 m	Valuation ($) N/A	Valuation ($) 4.6 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $62.6b (FY, 2025)	Revenue (est.) $294.3m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $502.1m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods $16.1b (FY, 2025)	Cost of goods $19.6m (FY, 2025)	Cost of goods N/A	Cost of goods $21m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit $46.5b (FY, 2025)	Gross profit $274.7m (FY, 2025)	Gross profit N/A	Gross profit $481.1m (FY, 2025)
Net income	Net income N/A	Net income $7.8b (FY, 2025)	Net income $367m (FY, 2025)	Net income N/A	Net income ($732.9m) (FY, 2025)
Funding
Total funding raised	Total funding raised $ 60m	Total funding raised N/A	Total funding raised $ 130m	Total funding raised $ 3.5m	Total funding raised $ 474.2m